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Comparison of distributions of dementia types in the systematic review [1]
and the Helsinki Businessmen Study [4]Although Alzheimer’s disease (AD) is frequently cited as
the most common type of dementia, the relative contribu-
tions of vascular and neurodegenerative pathology to clinical
dementia have been actually obscure. The systematic review
of studies reporting clinicopathologic data of dementia cases
sheds important light on this issue [1]. Ten reports were
analyzed, and altogether they included 2856 individuals,
1544 clinically demented and 1312 nondemented, with post-
mortem neuropathologic diagnosis.
The results showed that both vascular-type only and
Alzheimer-type only pathologies were associated with
similar prevalence of clinical dementias, whereas the great-
est risk of clinical dementia was observed among those with
mixed pathologies (AD plus vascular). Neuropathologic an-
alyses actually suggest that any multipathology (AD,
vascular, or Lewy-related) increases the risk of dementia
significantly [2].
We have earlier sought to discern various dementia types
and their risk factors in our longitudinal study of older men
(Helsinki Businessmen Study [HBS] [3]). The analyses were
based on diagnoses (not only as cause-of-death) and narra-
tives in death certificates [4]. We defined as “pure” AD, if
only AD was noted without any reference in the death certif-
icate to atherosclerotic cardiovascular disease (ASCVD); as
pure vascular, if dementia plus any ASCVD was noted; as
“mixed” if both AD and ASCVD were mentioned in the
death certificate. Minority of cases had other specific demen-
tia diagnosis or undefined dementia without concomitant
ASCVD or AD.
The distributions of clinicopathologic diagnoses of de-
mentia types in the systematic review and clinical diagnoses
in the HBS had a striking resemblance, and they are
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median age of 75 years to ASCVD risk factors measured
in midlife, at median age of 42 years. In adjusted analyses
only serum cholesterol was significantly related to dementia
with pure vascular or mixed features, whereas none of
midlife ASCVD risk factors, including glucose, were related
to pure AD during follow-up to old age [4].
The data from the systematic review and HBS support
prevention possibilities in more than half of dementia cases.
However, one quarter of cases seem to be because of
Alzheimer-type only dementia, which still eludes both
preventive and curative treatments. Immune system is a
probable contributor that deserves attention [5].Acknowledgments
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